CEL-SCI CORP (CVM)

US1508376076 - Common Stock

1.89  +0.01 (+0.53%)

Premarket: 1.93 +0.04 (+2.12%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CVM. CVM was compared to 592 industry peers in the Biotechnology industry. CVM has a bad profitability rating. Also its financial health evaluation is rather negative. CVM is valued expensive and it does not seem to be growing.



0

1. Profitability

1.1 Basic Checks

CVM had negative earnings in the past year.
CVM had a negative operating cash flow in the past year.
In the past 5 years CVM always reported negative net income.
In the past 5 years CVM always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -108.15%, CVM is not doing good in the industry: 81.29% of the companies in the same industry are doing better.
The Return On Equity of CVM (-245.45%) is worse than 72.96% of its industry peers.
Industry RankSector Rank
ROA -108.15%
ROE -245.45%
ROIC N/A
ROA(3y)-76.3%
ROA(5y)-76.74%
ROE(3y)-142.28%
ROE(5y)-202.3%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

CVM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

1

2. Health

2.1 Basic Checks

The number of shares outstanding for CVM has been increased compared to 1 year ago.
The number of shares outstanding for CVM has been increased compared to 5 years ago.
Compared to 1 year ago, CVM has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -23.70, we must say that CVM is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CVM (-23.70) is worse than 90.48% of its industry peers.
CVM has a Debt/Equity ratio of 0.75. This is a neutral value indicating CVM is somewhat dependend on debt financing.
CVM has a worse Debt to Equity ratio (0.75) than 77.04% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.75
Debt/FCF N/A
Altman-Z -23.7
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 1.26 indicates that CVM should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.26, CVM is doing worse than 87.24% of the companies in the same industry.
A Quick Ratio of 0.78 indicates that CVM may have some problems paying its short term obligations.
CVM's Quick ratio of 0.78 is on the low side compared to the rest of the industry. CVM is outperformed by 91.50% of its industry peers.
Industry RankSector Rank
Current Ratio 1.26
Quick Ratio 0.78

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 19.98% over the past year.
EPS 1Y (TTM)19.98%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q25.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to grow by 25.81% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y0.26%
EPS Next 2Y14.22%
EPS Next 3Y-8.53%
EPS Next 5Y25.81%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CVM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CVM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

CVM's earnings are expected to decrease with -8.53% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.22%
EPS Next 3Y-8.53%

0

5. Dividend

5.1 Amount

CVM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

CEL-SCI CORP

NYSEARCA:CVM (3/27/2024, 8:07:31 PM)

Premarket: 1.93 +0.04 (+2.12%)

1.89

+0.01 (+0.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap102.02M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -108.15%
ROE -245.45%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.75
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.26
Quick Ratio 0.78
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)19.98%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y0.26%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y